MX2007012457A - Polymyxin b analogs for lps detoxification. - Google Patents

Polymyxin b analogs for lps detoxification.

Info

Publication number
MX2007012457A
MX2007012457A MX2007012457A MX2007012457A MX2007012457A MX 2007012457 A MX2007012457 A MX 2007012457A MX 2007012457 A MX2007012457 A MX 2007012457A MX 2007012457 A MX2007012457 A MX 2007012457A MX 2007012457 A MX2007012457 A MX 2007012457A
Authority
MX
Mexico
Prior art keywords
lps
dimers
peptide
saep
leu
Prior art date
Application number
MX2007012457A
Other languages
Spanish (es)
Inventor
Noelle Mistretta
Monique Moreau
Massimo Porro
Tino Krell
Alessandro Rustici
Massimo Velucchi
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05300270A external-priority patent/EP1712559A1/en
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of MX2007012457A publication Critical patent/MX2007012457A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof

Abstract

The invention relates to SAEP II peptide dimers that mimic polymyxin B i.a. in its ability to bind non-covalently the lipopolysaccharide (LPS) of Gram-negative bacteria with high affinity, and therefore to detoxify LPS as polymyxin B does. The dimeric structure is maintained by a pair of disulphide bonds involving the two cystein residues present in the peptide sequence, which does not exceed 17 amino acids and essentially comprises cationic and hydrophobic amino acid residues. In the dimers of the invention, peptides may have a parallel or anti-parallel orientation. As a matter of example, a dimer of the invention is constituted by a peptide of formula NH2-Lys-Thr-Lys-Cysl-Lys-Phe-Leu- Leu-Leu-Cys2-COOH, either in a parallel or antiparallel dimeric form. SAEP II dimers are useful for treating or preventing septic shock and related disorders generated by Gram-negative bacteria infection. The invention also relates to LPS-peptide complexes in which LPS and SAEP II dimers are non-covalently bound together. These complexes are useful as vaccinal agents against Gram-negative bacteria infection.
MX2007012457A 2005-04-11 2006-04-10 Polymyxin b analogs for lps detoxification. MX2007012457A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05300270A EP1712559A1 (en) 2005-04-11 2005-04-11 Polymyxin B analogs for LPS detoxification
EP05300319 2005-04-26
PCT/EP2006/003237 WO2006108586A2 (en) 2005-04-11 2006-04-10 Polymyxin b analogs for lps detoxification

Publications (1)

Publication Number Publication Date
MX2007012457A true MX2007012457A (en) 2007-12-10

Family

ID=36968822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012457A MX2007012457A (en) 2005-04-11 2006-04-10 Polymyxin b analogs for lps detoxification.

Country Status (11)

Country Link
EP (1) EP1871787A2 (en)
JP (1) JP2008537749A (en)
KR (1) KR20070118646A (en)
AU (1) AU2006233634A1 (en)
BR (1) BRPI0610701A2 (en)
CA (1) CA2603850A1 (en)
IL (1) IL186322A0 (en)
MX (1) MX2007012457A (en)
NO (1) NO20075753L (en)
NZ (1) NZ561374A (en)
WO (1) WO2006108586A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5275982B2 (en) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
EP2429658B1 (en) 2009-05-14 2016-04-20 Sanofi Pasteur Method for adjuvating the lipopolysaccharide (LPS) of gram-negative bacteria
EP2430151B1 (en) 2009-05-14 2014-06-18 Sanofi Pasteur Meningococcal vaccine constituted of lipooligosaccharides from modified immunotype l6 neisseria meninigitidis
TWI548746B (en) * 2009-08-06 2016-09-11 英特威特國際股份有限公司 A vaccine directed against porcine pleuropneumonia and a method to obtain such a vaccine
AR113430A1 (en) * 2017-12-22 2020-04-29 Hanmi Pharm Ind Co Ltd THERAPEUTIC ENZYMATIC FUSION PROTEIN THAT HAS A NEW STRUCTURE AND ITS USE
WO2021187928A1 (en) * 2020-03-20 2021-09-23 단디바이오사이언스 주식회사 Composition and kit for removing lipopolysaccharide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5371186A (en) * 1991-02-11 1994-12-06 Biosynth S.R.L. Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
WO2004052394A1 (en) * 2002-12-06 2004-06-24 Biosynth S.R.L. Broad-spectrum lps based vaccines of unencapsulated strains of haemophilus influenzae and other pathogenic species of gram-negative bacteria

Also Published As

Publication number Publication date
KR20070118646A (en) 2007-12-17
CA2603850A1 (en) 2006-10-19
BRPI0610701A2 (en) 2010-07-20
AU2006233634A1 (en) 2006-10-19
WO2006108586A2 (en) 2006-10-19
NO20075753L (en) 2007-11-09
IL186322A0 (en) 2008-01-20
NZ561374A (en) 2009-02-28
EP1871787A2 (en) 2008-01-02
WO2006108586A3 (en) 2006-12-14
JP2008537749A (en) 2008-09-25

Similar Documents

Publication Publication Date Title
MX2007012457A (en) Polymyxin b analogs for lps detoxification.
ES2178000T3 (en) COMPOSITIONS AND METHODS TO TREAT INFECTIONS USING INDOLICIDINE ANALOGS.
MY161664A (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
GB0121591D0 (en) Hybrid and tandem expression of neisserial proteins
NO20063026L (en) antibodies
HK1140420A1 (en) Reconstituted surfactants having improved properties
ATE544780T1 (en) HYBRID POLYPEPTIDES WITH INSERTED SEQUENCE MOTIFS AND THEIR USES
MX345513B (en) Polypeptide.
PL378566A1 (en) Ligands for tgf-beta binding proteins and uses thereof
AR056137A1 (en) AN IMMUNOGLOBULIN PEPTIDE CONJUGATE AND ITS USE AS ANTIVIRAL
ATE489462T1 (en) ANTIMICROBIAL POLYPEPTIDE AND USE THEREOF
EA201390820A1 (en) Fusion protein against cancer
HK1093308A1 (en) Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock
JP2015519342A (en) Bioactive peptide complex
UA94716C2 (en) Calcium-peptide component for reducing body weight
MXPA05008080A (en) Peptide inhibitors of toxins derived from ll-37.
AR053355A1 (en) POLYMIXIN B ANALOGS FOR LPS DETOXIFICATION
WO2007033099A3 (en) Prodrugs of phentermine
JP2014501248A5 (en)
DE602006017806D1 (en) TREATMENT OF NEURODE GENERATION
TH84559B (en) An analogue of polymycin B for LPS toxic decomposition.
AR026068A1 (en) MODIFIED AND PEPTIDOMIMETIC PEPTIDES FOR USE IN IMMUNOTHERAPY.
TH84559A (en) An analogue of polymycin B for LPS toxic decomposition.
UA91497C2 (en) Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock
WO2019148195A3 (en) Cyclic peptidyl inhibitors of cal-pdz binding domain

Legal Events

Date Code Title Description
FA Abandonment or withdrawal